Results ESC sudden cardiac death risk scores were comparable between the HCM groups (HCM:2.2±1.5%, HCM-DM:1.9 ±1.2%; p=NS) and sarcomeric mutations were equally common. HCM-DM had the highest NT-proBNP levels (HV:42 ng/L [IQR:35–66 ng/L], DM:118 ng/L [IQR:53–187 ng/L], HCM:298 ng/L [IQR:157–837 ng/L], HCM-DM:726 ng/L [IQR:213–8695 ng/L]; p<0.0001). Left-ventricular ejection fraction, mass and wall thickness were similar between the HCM groups. HCM-DM displayed a greater degree of fibrosis burden with higher extracellular volume fraction and scar percentage, more significant reductions in global longitudinal strain and left atrial function compared to the isolated HCM. PCr/ATP was similarly decreased in the HCM-DM and DM (HV:2.17±0.49, DM:1.58±0.27, HCM:1.93±0.38, HCM-DM:1.54±0.27; p=0.0002). HCM-DM had the lowest stress myocardial blood flow (HV:2.06±0.42 ml/min/g, DM:1.95 ±0.41 ml/min/g, HCM:1.74±0.44 ml/min/g, HCM-DM:1.39 ±0.42 ml/min/g; p=0.0017).

Conclusions Comorbid diabetes adversely affects the HCM phenotype with greater reductions in myocardial energetics, perfusion, strain, increased scar burden and higher NT-proBNP levels compared to isolated HCM. Our findings suggest that specific, targeted therapeutic approaches may be useful in hypertrophic cardiomyopathy patients with diabetes comorbidity to improve clinical outcomes.

Doppler echocardiography (TTE) remains the imaging modality of choice for the assessment of mitral inflow and left ventricular diastolic function, despite its limitations. Four-dimensional flow cardiovascular magnetic resonance (4D flow CMR) offers time-resolved cross-sectional velocity data, which can be used to investigate transvalvular peak velocity through the mitral valve. This would not suffer from the in-plane motion and angle-dependence of pulse-wave echocardiography.

Objective We aim to validate a novel time-resolved, automated dynamic 4D flow CMR peak velocity tracking method for measuring the peak velocity of mitral inflow against TTE.

Method Patients recruited to EurValve programme (n=22) underwent TTE and 4D flow CMR. Peak E-wave and A-wave velocities were recorded. This work was done in collaboration with the industry leader in 4D flow CMR (PIE Medical Imaging). Transvalvular flow segmentation was done using established valve tracking methods and the generated 3D streamlines were investigated for seeking the peak velocity inside the left ventricular cavity during diastole. Reproducibility analyses were carried out in 10 cases.

Results The peak E-wave mitral inflow velocity was comparable between the novel 4D flow method and TTE (1.09 ± 0.29 m/s and 1.10 ± 0.37 m/s respectively; p=0.60). The mean A-wave peak velocity was also comparable across both methods (0.94 ± 0.40 m/s and 0.86 ± 0.29 m/s respectively; p=0.38). The automated 4D flow method also showed good correlation with TTE for both E-wave (r=0.54; p=0.01) and A-wave (r=0.55; p=0.03) with
Automated peak velocity tracking using 4D flow CMR was validated in 22 patients against pulse-wave Doppler Echocardiography for mitral inflow assessment.

Mean bar chart and scatter plots demonstrating agreement between PW-Doppler and novel automated 4D flow CMR method.

Bland-Altman plots demonstrate minimal and statistically non-significant bias between PW-Doppler and novel 4D flow method for peak mitral inflow assessment.
minimal and non-significant bias between the two modalities (bias=0.01 m/s; p=0.91 and −0.08 m/s; p=0.91). This novel automated method demonstrated excellent reproducibility (Coefficient of variability 2.67% for peak E-wave mitral inflow velocity, Coefficient of variability 1.93% for peak A-wave mitral inflow velocity).

Conclusion We present a novel automated time-resolved transvalvular peak velocity assessment solution that can be used clinically for mitral inflow assessment and would circumvent the limitations of pulse-wave doppler echocardiography. Future studies are warranted to explore the diagnostic and prognostic advantages of our novel automated technique for mitral inflow assessment.

17 PARTICIPANTS WITH DIABETES MELLITUS HAVE PRESERVED METABOLIC FLEXIBILITY

Peregrine Green, William D Watson, Neil Herring, Stefan Neubauer, Oliver J Rider. Oxford Centre for Clinical Magnetic Resonance Research, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, UK; Department of Physiology, Anatomy and Genetics, University of Oxford, UK

Background Measurement of the Phosphocreatine/Adenosine Triphosphate (ATP) ratio along with the Creatine Kinase (CK) rate constant (CK\textsubscript{k}) allows calculation of the ATP delivery rate (CK flux). Metabolic flexibility may be impaired both in heart failure with reduced ejection fraction (HFrEF) and diabetes mellitus (DM). It is unknown to what extent flexibility can be influenced by artificially altering the substrate available for metabolism.

Purpose To examine cardiac function and energetics in diabetic participants with normal cardiac function and HFrEF, clamped on either fatty acid (FA) or glucose metabolism.

Methods Participants with non-insulin dependent diabetic mellitus (NIDDM) with both normal cardiac function (NHDM) and HFrEF (HFDM) were recruited and received intravenous infusions of either Intralipid (IL) or glucose-insulin (GI) at 2 separate visits, before undergoing multi-parametric cardiac MRI at 3 Tesla. Cardiac volume and function, PCR/ATP and CK flux were calculated as CK\textsubscript{k} x PCR/ATP x 5.7 μmol (g wet weight)\textsuperscript{-1} (assumed ATP concentration).

Results 15 NHDM participants (14 male, age 61.5 ± 7.3 years) and 9 HFDM participants (7 male, age 69.4 ± 7.8 years) were recruited. Left ventricular ejection fraction (LVEF) at rest was higher on IL compared to both baseline fasting and GI for NHDM (baseline 59.1±3.8%, GI 59.4±4.3%, IL 62.8±3.5%; p=0.01), with a non-significant trend for HFDM (baseline 37.3±7.6%, GI 36.8±9.2%, IL 38.8±8.0%, p=0.12). For both NHDM and HFDM there was no difference in PCR/ATP (NHDM: GI 1.98±0.31, IL 1.97±0.24, p=0.099; HFDM: GI 1.82±0.36, IL 2.01±0.32, p=0.09) or CK flux (NHDM: GI 2.6±1.1 μmol (g wet weight)\textsuperscript{-1} s\textsuperscript{-1}, IL 1.8±1.2 μmol (g wet weight)\textsuperscript{-1} s\textsuperscript{-1}, p=0.08; HFDM: GI 1.6±1.7 μmol (g wet weight)\textsuperscript{-1} s\textsuperscript{-1}, IL 2.3±1.1 μmol (g wet weight)\textsuperscript{-1} s\textsuperscript{-1}, p=0.39).

Conclusion Diabetic participants with HFrEF and normal cardiac function appear to have increased resting LVEF when clamped on FA as opposed to glucose metabolism, without a significant change in energetic status. This may imply that metabolic flexibility is relatively preserved in these groups.

18 SUBCLINICAL MYOCARDIAL INFLAMMATION IN ADULTS WITH TYPE 2 DIABETES: A CLINICAL STUDY USING MYOCARDIAL T2 MAPPING

Pranav Ramesh, Jian L Yeo, Gaurav S Gulsin, Gerry P McCann. Department of Cardiovascular Sciences, University of Leicester and Leicester NIHR Biomedical Research Centre, Glenfield Hospital, Leicester, UK

Background Chronic hyperglycaemia in Type 2 diabetes (T2D) results in a systemic low-grade inflammatory state. Inflammation is a key instigator in the development of heart failure in T2D. Cardiovascular magnetic resonance (CMR) T2 mapping is a technique which identifies myocardial oedema. The utility of T2 mapping to identify subclinical oedema as a marker of inflammation in T2D is unknown. We hypothesise that T2 times will be higher in subjects with T2D.

Methods CMR imaging on a 3-Tesla scanner was performed on 182 participants who were free of symptomatic cardiovascular disease. T2 images were acquired using the Siemens MyoMap sequence at the mid-ventricular short-axis slice. Twenty participants underwent a repeat CMR scan within two weeks to assess the test-retest reproducibility of T2. Intraclass correlation coefficient (ICC) and Bland-Altman plots were generated to assess reproducibility. T2 values between groups were compared using T-test or Mann-Whitney test as appropriate. Clinical determinants of T2 in T2D were assessed using multivariable linear regression.

Results 124 T2D (mean age 64±7, 66% male) and 40 controls (mean age 61±8, 60% male) were analysed. T2 times exhibited excellent intra-observer (ICC 0.98–0.99), moderate inter-observer (ICC 0.48–0.99), and poor test-retest variability (ICC 0.33–0.90). T2 times were significantly lower in subjects with T2D compared to controls (39.0±2.2 ms versus 40.1±2.9 ms, P=0.013). Stratification by sex revealed significantly lower T2 in females with T2D (39.4±2.4 ms versus 41.7±3.1 ms, P=0.003), but not in males, when compared to controls. Following multivariable adjustment, T2 time was positively associated with a non-white ethnicity (β=0.245, P=0.007) and diabetic duration (β=0.197, P=0.03) and inversely associated with systolic blood pressure (β=−0.215, P=0.018).

Conclusions T2 mapping has moderate-excellent observer variability but poor test-retest reproducibility in a cohort T2D. Lower T2 times in T2D may reflect early myocardial fibrosis but does not provide evidence of subclinical myocardial oedema and therefore is not able to detect low-grade myocardial inflammation.

19 CARDIAC MAGNETIC RESONANCE TO IDENTIFY RAISED LEFT VENTRICULAR FILLING PRESSURE


Background Non-invasive imaging is routinely used to estimate left ventricular (LV) filling pressures (LVFP) in heart failure (HF), as an alternative to right heart catheterisation (RHC). Transthoracic echocardiography (TTE) estimates of LVFP are frequently deployed but produce largely dichotomised data limiting flexible clinical use and perform less well in patients with heart failure with preserved ejection fraction (HFrEF),